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Abstract: Healthcare-associated infections (HAIs) occurring in patients treated in an intensive care
unit (ICU) are serious complications in the treatment process. Aetiological factors of these infections
can have an impact on treatment effects, treatment duration and mortality. The aim of the study
was to determine the prevalence and microbiological profile of HAIs in patients hospitalized in
an ICU over a span of 10 years. The active surveillance method was used to detect HAIs in
adult patients who spent over 48 h in a general ICU ward located in southern Poland between
2007 and 2016. The study was conducted in compliance with the methodology recommended by
the Healthcare-associated Infections Surveillance Network (HAI-Net) of the European Centre for
Disease Prevention and Control (ECDC). During the 10 years of the study, 1849 patients hospitalized
in an ICU for a total of 17,599 days acquired 510 with overall HAIs rates of 27.6% and 29.0%
infections per 1000 ICU days. Intubation-associated pneumonia (IAP) posed the greatest risk
(15.2 per 1000 ventilator days), followed by CLA-BSI (8.0 per 1000 catheter days) and CA-UTI (3.0 per
1000 catheter days). The most common isolated microorganism was Acinetobacter baumannii (25%)
followed by Coagulaase-negativ staphylococci (15%), Escherichia coli (9%), Pseudomonas aeruginosa
(8%), Klebsiella pneumoniae (7%), Candida albicans (6%). Acinetobacter baumannii in 87% and were
classified as extensive-drug resistant (XDR). In summary, in ICU patients pneumonia and bloodstream
infections were the most frequently found. Acinetobacter baumannii strains were most often isolated
from clinical materials taken from HAI patients and showed resistance to many groups of antibiotics.
A trend of increasing resistance of Acinetobacter baumannii to carbapenems was observed.
Keywords: healthcare-associated infections; hospital infection intensive care unit; bloodstream
infection urinary tract infection; ventilator-associated pneumonia; antibiotic resistance;
Acinetobacter baumannii
1. Introduction
According to multiple sources, between 20% and 50% of healthcare-associated infections (HAIs)
occur in the intensive care unit (ICU). In 2007, 39% of patients in European countries were affected
by these infections [1]. In Poland HAIs were detected in 24–45% of ICU patients [2,3]. Meta-analysis
of HAIs showed that a HAIs affected 30% of patients [4]. In Italy frequency of HAIs was lower
(16%) [5]. These infections presented in the most dangerous and sometimes life-threatening forms of
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infection, such as pneumonia, bloodstream infection, and urinary tract infection; therefore, surveillance
of these types of infections is important in the ICU [6,7]. The prevention of these infections is
correlated with high treatment costs and longer hospitalization times [8]. Among healthcare-associated
infections, PN is the most common and accounts for between 30% and 50% of all infections [6,8–11].
Epidemiological studies indicate that bloodstream infections are low frequently found and their
prevalence ranges from 4% to 20% [6,8,10,11]. Among HAIs, the prevalence of urinary tract infections
ranges from 3% to 7% [8,10,11]. Studies by Gordats et al. [10] showed that, among individuals with
reduced immunity, which included ICU patients, other forms of HAIs also appeared.
The development of HAIs can be facilitated by the ICU environment, medical procedures applied
to treat the patient and, above all, the patient’s general health. Intensive care units treat severely ill
patients whose underlying disease and coexisting diseases may contribute to the development of
healthcare-associated infections [10,12]. The need to perform many diagnostic and treatment activities
on patients results in the use and long-term maintenance of invasive devices, such as central vascular
lines (CVC), intubation tubes, and urethral catheters (which may result in the removal of the natural
protective barrier against infections [13]. Patients’ stays in the ICU are often preceded by hospitalization
in other hospital wards, during which there are often problems with the treatment of such patients.
During the patient’s stay in hospital (regardless of the ward in which they are hospitalized), the bacterial
physiological microbiota are replaced with the hospital microbiota typical of a given ward. In addition,
long-term antibiotic treatment leads to the selection of sensitive microorganisms in the patient’s
organisms, which may facilitate a conquest of the organism by pathogenic microorganisms (also by
those coming from the environment) with a proven mechanism of resistance to antibiotics [13,14].
Therefore, it is extremely important to undertake actions that will at least protect patients from the
negative health effects of microorganisms coming from a hospital environment; this is especially true
for patients in intensive care units, where the invasiveness of treatments and reduced immunity of the
patient will predispose them to an increased number of colonizations and infections. The results of the
analysis demonstrated below are among few such studies in Poland and can be used as a reference to
the actual epidemiological situation prevailing in ICU units of other hospitals in Poland, Europe or
other continents. The aim of the study was to determine the incidence and microbiological profile of
healthcare-associated infections in an intensive care unit.
2. Materials and Methods
The active surveillance method was used to detect HAIs in adult patients who spent over 48 h
in a 9-bed general ICU ward located in southern Poland between 2007 and 2016. The ward under
study was part of a multi-profile hospital (670 hospital beds). Not all patients included in the study
were examined with the application of SOFA and APACHEII scales, therefore these scales were not
taken under consideration. Definitions developed by the ECDC were used to identify and qualify
infections [6,7]. The data collection methodology was fully compliant with the European Centre
for Disease Prevention and Control (ECDC) recommended by the Healthcare-associated Infections
Surveillance Network (HAI-Net) [7]. The HAI study was divided into the main and specific types of
HAIs, such as BSI, PN, UTI, and OTH (other infections). Among the OTH infections, the following
were distinguished: CNS, EENT, LRI, SYS.
Bloodstream infection was defined as a patient has at least one positive blood culture for a
recognised pathogen or patient has at least one of the following signs or symptoms: fever (>38 ◦C),
chills, or hypotension and two positive blood cultures for a common skin contaminant (from two
separate blood samples, usually within 48 h). Skin contaminants = coagulase-negative staphylococci,
Micrococcus spp., Propionibacterium acnes, Bacillus spp., Corynebacterium spp. [7].
Pneumonia (PN1–PN5) was defined as two or more serial chest X-rays or CT-scans with a
suggestive image of pneumonia for patients with underlying cardiac or pulmonary disease. In patients
without underlying cardiac or pulmonary disease, one definitive chest X-ray or CT-scan is sufficient.
And at least one of the following: fever >38 ◦C with no other cause leukopenia (<4000 WBC/mm3)
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or leucocytosis (≥12,000 WBC/mm3) and at least one of the following (or at least two, if clinical
pneumonia only = PN4 and PN5): new onset of purulent sputum, or change in character of sputum
(colour, odour, quantity, consistency), cough or dyspnea or tachypnea suggestive auscultation (rales or
bronchial breath sounds), rhonchi, wheezing, worsening gas exchange (e.g., O2 desaturation or
increased oxygen requirements or increased ventilation demand) and according to the used diagnostic
method [7].
Urinary tract infection (UTI) was defined as a microbiologically confirmed symptomatic urinary
tract infection where the patient has at least one of the following symptoms with no other recognised
cause: fever (>38 ◦C), urgency, frequency, dysuria, or suprapubic tenderness and patient has a
positive urine culture, i.e., ≥105 microorganisms per mL of urine with no more than two species
of microorganisms [7].
A device-associated, healthcare-associated infection is an HAI in a patient with a (relevant) device
that was used within a 48-h period before the onset of infection. The term ‘deviceassociated’ is
only used for pneumonia, bloodstream infections, and urinary tract infections. ‘Relevant devices’
refers to intubation, central vascular catheters, and urinary catheters. If the interval is longer than
48 h, there must be compelling evidence that the infection was associated with the device use.
For catheter-associated UTI, an indwelling urinary catheter must have been in place seven days
before positive laboratory results or signs and symptoms meeting the criteria for UTI were evident.
Example: Pneumonia is defined as intubation-associated (IAP) if an invasive respiratory device was
present (even intermittently) in the 48 h preceding the onset of infection [7].
Blood infections were monitored as Catheter Related Infections (CRIs) including the division into
types of catheters used and microbiological diagnosis.
The results of microbiological studies performed with clinically relevant materials, such as
blood, urine, smear from wounds, faeces, broncho-aspirate, vascular lavage, vascular catheter tips
and others, were interpreted. The hospital applied the principles of the European Committee on
Antimicrobial Susceptibility Testing (EUCAST). Strains resistant to antibiotics were defined in the
following way: Extensive Drug Resistant (XDR)—resistant to one or more antibiotics in all groups
of antibiotics; multi drug resistant (MDR)—resistant to at least one antibiotic from three or more
groups of antibacterial drugs active for a particular type of microbial genus or Pan Drug Resistant
(PDR)—resistant to all antibiotics in all groups of antibiotics active for a particular genus. Microbial
cultures were incubated on chromogenic media: Chromid ID CPS, Columbia with 5% of ram blood,
Sabouraud agar, Schaedler agar, trypicase soy agar, chocolate agar, MacConkey agar, Hektoen enteric
agar, sodium selenate agar. Microorganisms were identified by means of biochemical tests applied in
automatic system of identification: Vitek 2 Compact (bioMérieux, Marcy-l’Étoile, France).
The following epidemiological indicators were used to investigate the epidemiological situation:
cumulative incidence and incidence density. The incidence = number of HAI × 100 per number of
patients. The incidence density of HAIs per 1000 days of device use. Density CLA-BSI = number of
CLA-BSI × 1000 per number of central line-days. Density IAP = number of IAP × 1000 per number of
intubation-days (VAP w CDC/INICC). Density CA-UTI = number of CA-UTI × 1000 per number of
urinary catheter-days. Mortality (% death of HAIs = number of deaths HAI × 100 per number of HAI).
Device utilization ratio (DUR) = number of an invasive device days (CVC, intubation, urinary catheter)
per number of patient days. All the data that were entered into an electronic database and analyses in
this study were anonymized previously.
Statistical Package for the Social Sciences (SPSS STATISTICS 24, Armonk, NY, USA) and Microsoft
Excel Microsoft Office 2016 (Redmond, WA, USA) were used in the statistical analysis of the
collected material. The significance level was p < 0.05. In addition, the pooled mean, median (Me),
standard deviation (SD), 95% confidence interval for mean (95% CI), odds ratio (OR), Chi-squared
(Pearson) χ2 for the ordinal and nominal scales and an ANOVA for the quantitative scale were
calculated. The invasive procedures performed on patients were analyses as risk factors for HAI
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formation and calculated for Chi-squared (Pearson)’s materiality level, the quotient of chances and
Pearson’s correlations.
3. Results
During the 2007–2016 period 1847 patients were treated in the ICU, for more than 48 h each;
710 patients (38.4%) were females, and 1137 patients (61.6%) were males. The HAI risk was statistically
significantly higher for men (p < 0.001) than for women, and the odds of HAI (OR) were greater for
men than for women and amounted to 1.55 (95% CI 1.24–1.92). The average age of patients hospitalized
in the ICU was 58 (median 61 years, SD 20, and 95% CI 57–59). Patients with HAIs were younger
and were, on average, 54 years old (median 57 years, SD 18.495, and 95% CI 52.8–56.1) than patients
without HAIs, who were on average 59 years old (median age 62, SD 19.840, 95% CI 58.2–60.2); this
difference was statistically significant (p < 0.001).
In the group of 1847 patients under survey, 510 cases of HAI were diagnosed, and the HAI
incidence rate was 27.6% in 100 patients admitted to the ICU. The main types of HAI detected
in ICU patients included the following: PN (9.9% incidence), BSI (8.9% incidence) and UTI
(2.9% incidence). The central line-associated bloodstream infection (CA-BSI) incidence density was
8.0/1000 catheter-days, the device use ratio (DUR) was 0.96, the ventilator-associated pneumonia (VAP)
incidence density was 15.2/1000 ventilator-days, (DUR 0.65) and the catheter-associated urinary tract
infection (CA-UTI) incidence density was 3.0/1000 catheter-days. In the material under examination,
other types of HAI accounted for 22% of all infections, and the percentage of these infections was
similar in all the years under analysis (Table 1).
Table 1. Number of HAIs/100 admissions (%), number of HAIs/1000 person days (n/1000), person
days (n) by major and specific sites of infection in an intensive care unit in the years 2007–2016.
HAI Types N
Incidence
(%) per 100
Admissions
to ICU
Incidence
Density per
1000 Days in
ICU
Number of
Person Days
with
Invasive
Device *
Incidence
Density per
1000 Person
Days with
Device
DUR
All HAIs 510 27.6 29.0
Pneumonia (PN) 183 9.9 10.4
PN1: minimally
contaminated LRT
sample with quantitative
culture
13 0.7 0.7
12,059 15.2 * 0.65
PN2: non-protected
sample with quantitative
culture
14 0.8 0.8
PN3: alternative
microbiological criteria 6 0.3 0.3
PN4: sputum
bacteriology or
non-quantitative
145 7.9 8.2
PN5: no microbiological
documentation 5 0.3 0.3
Bloodstream
infections (BSI) 159 8.6 9.0
BSI-C: Primary BSI
catheter-related 24 1.3 1.4
17,858 8.0 ** 0.96BSI-UO: Primary BSI of
unknown origin 118 6.4 6.7
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Table 1. Cont.
HAI Types N
Incidence
(%) per 100
Admissions
to ICU
Incidence
Density per
1000 Days in
ICU
Number of
Person Days
with
Invasive
Device *
Incidence
Density per
1000 Person
Days with
Device
DUR
BSI-S: secondary BSI 17 0.9 1.0 n/a n/a n/a
Urinary tract
infection (UTI) 54 2.9 3.1
UTI-A: microbiologically
confirmed symptomatic 54 2.9 3.1 18,192 3.0 *** 0.98
UTI-B: not
microbiologically
confirmed symptomatic
0 0,0 0.0
Gastrointestinal (GI) 38 2.1 2.2
GI-CDI: clostridium
difficile infection 20 1.1 1.1 n/a n/a n/a
GI-GE: gastroenteritis 18 1.0 1.0 n/a n/a n/a
Surgical site
infection (SSI) 33 1.8 1.9
SSI-D: Deep incisional 18 1.0 1.0 n/a n/a n/a
SSI-O: Organ/space 6 0.3 0.3 n/a n/a n/a
SSI-S: Superficial
incisional 9 0.5 0.5 n/a n/a n/a
Skin and soft tissue
infection (SST) 25 1.4 1.4
SST-DECU: soft tissue 17 0.9 1.0 n/a n/a n/a
SST-SKIN: skin infection 5 0.3 0.3 n/a n/a n/a
SST-ST: soft tissue 3 0.2 0.2 n/a n/a n/a
Other infections (OTH) 18 1.0 1.0
Number of patients in ICU = 1847; the number of days in ICU = 17,599, HAI: hospital acquired infections; N:
number; * per 1000 ventilator days; ** per 1000 central line days; *** per 1000 catheter days; n/a: not applicable; LRT:
lower respiratory tract, device use ratio (DUR).
The analysis identified risk factors, which included invasive procedures and potentially a
significant factor in HAI formation. Statistically significant differences occurred between patients
without and with HAIs in the following invasive procedures: mechanical ventilation, urethral catheter,
administration of blood and plasma, pleural drainage, tracheostomy, percutaneous endoscopic
gastrostomy (PEG), bronchoscopy, parenteral nutrition, and gastroscopy. Poor impact strength
(Pearson’s correlation) was found for the administered blood, plasma, pleural drainage, PEG probes,
bronchoscopy and gastroscopy, indicating that the tendency to acquire HAI is evident with the use
of these devices; there are, however, deviations. Moderate dependence was detected in the case of a
patient who had tracheostomy, in which case the tendency to acquire an HAI was most visible (Table 2).
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Table 2. HAI risk factors in the ICU, 2007–2016.
Risk Factor
Patients without HAI HAIPatients Total OR (95% CI) p Pearson’s
Correlation
n (%) n (%) n (%)
Central catheter 885 (72.5%) 335 (27.9%) 1220 (100%) 1.0 (0.8–1.2) 0.869 0.0
Arterial catheter 443 (71.0%) 181 (29.0%) 624 (100%) 1.1 (0.9–1.4) 0.595 0.0
Intubation 287 (86.2%) 134 (31.8%) 421 (100%) 1.3 (1.0–1.7) 0.265 0.1
Mechanical ventilation 887 (69.8%) 383 (30.2%) 1270 (100%) 1.5 (1.2–1.9) <0.05 0.1
Urethral catheter 259 (65.9%) 134 (34.1%) 393 (100%) 1.5 (1.2–1.9) <0.001 0.1
Stomach probe 447 (71.0%) 183 (29.0%) 630 (100%) 1.1 (0.9–1.4) 0.884 0.0
Blood 310 (53.0%) 275 (47.0%) 585 (100%) 3.9 (3.1–4.8) <0.001 0.3
Pleural drainage 67 (46.5%) 77 (53.5%) 144 (100%) 3.4 (2.4–4.8) <0.001 0.2
Tracheostomy 98 (27.9%) 253 (72.1%) 351 (100%) 12.4 (9.5–16.3) <0.001 0.5
Peg 38 (30.6%) 86 (69.4%) 124 (100%) 6.9 (4.7–10.3) <0.001 0.3
Plasma 196 (54.0%) 167 (46.0%) 363 (100%) 2.8 (2.2–3.6) <0.001 0.2
Bronchoscopy 117 (39.1%) 182 (60.9%) 299 (100%) 5.8 (4.5–7.5) <0.001 0.3
Parenteral nutrition 101 (57.4%) 75 (42.6%) 176 (100%) 2.1 (1.5–2.9) <0.001 0.1
Gastroscopy 37 (26.4%) 103 (73.6%) 140 (100%) 8.9 (6.0–13.2) <0.001 0.3
Chi-square (p); Odds ratio (OR); 95% confidence interval (CI); percutaneous endoscopic gastrostomy (PEG).
A total of 93% of HAIs were caused by micro-organisms that were determined by being
identified as a genus or species. A total of 7% of HAI infections were not microbiologically
confirmed. BSI was dominated by Coagulase-negative staphylococci (44%), PN was dominated by
non-fermenting gram-negative bacteria including Acinetobacter baumannii (41%), UTI was dominated
by Enterobacteriaceae including Escherichia coli (19%), SSI was dominated by A. baumannii (25%),
GI was dominated by Clostridium difficile (70%), SST was dominated by E. coli (20%) and Klebsiella
pneumoniae (20%), and OTH was dominated by K. pneumoniae (18%) (Table 3).
Table 3. Microorganisms isolated in HAI in the ICU, 2007–2016.
Number of HAI with
Microorganisms, All N
BSI PN UTI SSI GI SST OTH
156 174 54 32 27 25 18
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Gram-positive cocci (n) 138 79 21 0 2 0 2 4
Coagulase-negative
staphylococci (%) 70 69 (44.2) 1 (5.6)
Staphylococcus aureus (%) 33 10 (6.4) 16 (9.2) 2 (6.3) 2 (8.0) 3 (16.6)
Enterococcus spp. (%) 32 2 (1.1)
Streptococcus pneumoniae (%) 3 3 (1.7)
Gram-positive other (n) 19 0 0 0 0 19 0 0
Clostridium difficile (%) 19 19 (70.4)
Enterobacteriaceae (n) 117 24 46 20 8 0 13 8
Escherichia coli (%) 44 8 (5.1) 16 (9.2) 10 (18.5) 4 (12.5) 5 (20.0) 1 (5.6)
Klebsiella pneumoniae (%) 35 8 (5.1) 14 (8.0) 2 (3.7) 1 (3.1) 5 (20.0) 7 (17.9)
Enterobacter spp. (%) 18 4 (2.6) 7 (4.0) 4 (7.4) 1 (3.1) 2 (8.0)
Proteus spp. (%) 11 7 (4.0) 2 (3.7) 1 (3.1) 1 (4.0)
Seratia spp. (%) 5 3 (1.9) 1 (0.6) 1 (3.1)
Citrobacter spp. (%) 4 1 (0.6) 1 (0.6) 2 (3.70)
Non-fermenting
gram-negative bacteria (n) 165 33 96 10 13 0 6 7
Acinetobacter baumannii (%) 120 27 (17.3) 72 (41.4) 4 (7.4) 8 (25.0) 4 (16.0) 5 (27.7)
Pseudomonas aeruginosa (%) 39 5 (3.2) 20 (11.5) 6 (11.1) 5 (15.6) 1 (4.0) 2 (11.1)
Morganella morgannii (%) 3 1 (0.6) 1 (0.6) 1 (4.0)
Stenotrophomonas maltophilia (%) 2 2 (1.1)
Hemophilus spp. (%) 1 1 (0.6)
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Table 3. Cont.
Number of HAI with
Microorganisms, All N
BSI PN UTI SSI GI SST OTH
156 174 54 32 27 25 18
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Other bacteria (n) 9 3 3 0 2 0 1 0
Other bacteria (%) 9 3 (1.9) 3 (1.7) 2 (6.3) 1 (4.0)
Fungi (n) 31 6 5 11 3 5 0 0
Candida albicans (%) 28 6 (3.8) 5 (2.9) 11 (20.4) 1 (3.1) 5 (18.5)
Candida glabrata (%) 2 2 (6.3)
Candida krusei (%) 1
Viruses (n) 2 0 0 0 0 2 0 0
Adenovirus 1 1 (3.7)
Norovirus 1 1 (3.7)
N: number; pneumonia (PN); blood stream infections (BSI); urinary tract infection (UTI); Gastrointestinal (GE);
Surgical site infection (SSI); skin and soft tissue infection (SST); Other infections (OTH).
The average time between admission of a patient to the ICU and emergence of HAI was
22.9 days (median 17 days) and was statistically significantly different for each type of HAI (p < 0.001).
The average duration of an ICU patient’s stay was 28.2 days (median 17 days). Patients with HAIs
stayed in the ICU statistically significantly longer than those without HAIs (p < 0.001) (Table 4).
Table 4. Days until HAI onset, ICU length of stay, mortality related to the microorganism that gave rise
to HAI in the ICU in the years 2007–2016.
Infection Types
N
Average Number of Days between
Admission to HAI Emergence
Average Number of Days of
Patient’s Stay in ICU
Pooled Mean
(95% CI) SD
Pooled Mean
(95% CI) SD
type HAI
Patients without HAI 1337 n/a n/a 19.0 (17.9–20.1) 21.1
Pneumonia 183 19.2 (16.7–21.7) 17.3 51.5 (45.8–57.2) 39.0
Blood stream infections 159 24.1 (20.2–27.9) 24.7 49.2 (42.9–55.6) 39.7
Urinary tract infection 54 30.4 (23.9–36.8) 23.6 62.3 (50.9–73.6) 41.2
Gastrointestinal 38 13.7 (11.2–16.3) 7.7 42.2 (29.8–55.0) 37.8
Surgical site infection 33 26.3 (21.4–31.2) 13.8 67.0 (50.7–83.3) 45.9
Skin and soft tissue infection 25 42.0 (29.2–54.8) 31.1 73.2 (55.7–90.6) 41.3
Other infections 18 14.3 (7.5–21.1) 13.7 34.5 (23.6–51.6) 28.2
Total 1847 22.9 (21.0024.8) 21.0 28.2 (26.8–29.7) 31.5
Materiality ANOVA (p) n/a p < 0.001 n/a p < 0.001 n/a
selected aetiological HAI factors
Clostridium difficile 19 12.4 (8.4–16.4) 8.3 35.5 (19.2–51.8) 32.7
Staphylococcus aureus 33 19.0 (16.1–22.0) 16.2 50.3 (33.4–80.6) 40.8
Staphylococcus CNS 70 20.8 (16.4–32.5) 28.5 47.5 (35.7–58.5) 39.5
Enterobacter spp. 18 22.7 (15.6–23.1) 15.7 58.3 (42.0–71.9) 43.3
Acinetobacter baumannii 120 23.6 (17.6–29.6) 19.7 40.0 (37.2–51.0) 22.7
Escherichia coli 44 24.3 (18.0–29.0) 15.3 53.7 (46.3–61.1) 40.6
Klebsiella pneumoniae 35 27.1 (13.2–37.5) 25.3 67.8 (46.4–77.8) 45.1
Candida albicans 28 31.5 (23.0–39.9) 26.2 57.5 (45.9–69.1) 38.3
Pseudomonas aeruginosa 39 35.9 (24.4–44.4) 29.7 59.7 (42.3–73.5) 42.8
Enterococcus spp. 32 36.2 (25.5–45.6) 30.2 66.3 (52.3–80.2) 43.1
N: number; Me: median; SD: standard deviation; 95% confidence interval (CI) for mean; n/a: not applicable; CNS:
coagulase-negative staphylococci.
The number of days that elapsed before the infection and the duration of a patient’s stay in the
ICU were different for each species (or genus) of microorganism. In patients with HAIs, the mortality
rate was 42.5%, and in the non-infected group, the mortality rate was 45.3%; this difference was not
Int. J. Environ. Res. Public Health 2018, 15, 112 8 of 16
statistically significant (p = 0.296). The index calculated for each species (species) of the microorganism
showed that the highest mortality rate was observed in patients with fungal infections (Table 5).
Table 5. Antimicrobial resistance in HAI in the ICU, 2007–2016.
Microbial Genus/Species Number ofIsolates, Total
Number of
Isolates with
Resistance
Mechanism
Resistant Codes
n (%) n (%)
Gram-positive cocci
Staphylococcus aureus 33 10 (30.3)
MRSA 7 (21.1)
MLSB 3 (9.1)
Coagulase-negative
staphylococci (%) 70 30 (42.8)
MRSA 25 (35.7)
MLSB 5 (7.1)
Enterococcus spp. 32 10 (31.2) HLAR 10 (31.2)
Enterobacteriaceae
Escherichia coli 44 3 (6.8) ESBL 3 (6.8)
Klebsiella pneumoniae 35 10 (28.6)
MBL 2 (5.7)
ESBL 8 (22.9)
Non-fermenting gram-negative bacteria
Acinetobacter baumannii. 120 5 (4.1) MBL 5 (4.1)
Enterobacter spp. 18 3 (16.6) ESBL 3 (16.6)
MRSA: methicillin-resistant Staphylococcus aureus; ESBL: extended beta-lactamase produced; HLAR: high-level
aminoglycoside resistance; MBL: metalo-beta lactamase.
Antibiotic resistance mechanisms were identified for the most common microorganisms (Table 5).
Antibiotic susceptibility analysis was performed for the three most common Gram-negative organisms.
Acinetobacter baumannii strains were characterized by high rates of resistance to many groups of
antibiotics, 87% of which were extensive-drug resistant (XDR) strains. Similarly, 25% of K. pneumoniae
strains were included in XDR, and 17% were multi-drug resistant (MDR). Pseudomonas aeruginosa
strains were mostly antibiotic-sensitive, with resistance affecting 30% of the strains classified as MDR
strains (Table 6).
Table 6. Resistance to a selected group of antibiotics and type of multi-drug resistance in the ICU in
the years 2007–2016.
Antibiotic Name Acinetobacterbaumannii (N = 120)
Pseudomonas
aeruginosa (N = 39)
Klebsiella
pneumoniae (N = 44)
Aminoglycosides (%)
Gentamicin 63.7 25.0 25.0
Tobramycin 81.1 10.0 33.3
Amikacin 95.6 15.0 25.0
Netilmicin 88.4 20.0 16.6
Antipseudomonal carbapenems (%)
Imipenem 30.4 35.0 0.0
Mero penem 33.3 20.0 8.3
Extended-spectrum cephalosporins (%)
Ceftazidime 98.1 15.0 41.6
Cefepime 94.5 25.0 16.6
Cefotaxime 99.3 75.0 58.3
Ceftriaxone 97.8 65.7 66.6
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Table 6. Cont.
Antibiotic Name Acinetobacterbaumannii (N = 120)
Pseudomonas
aeruginosa (N = 39)
Klebsiella
pneumoniae (N = 44)
Antipseudomonal fluoroquinolones (%)
Ciprofloxacin 97.8 10.0 41.6
Levofloxacin 95.6 10.0 8.3
Penicillins (piperacillin) (%)
Piperacillin 0.0 20.0 0.0
Penicillins and b-lactamase inhibitors (%)
Ticarcillin clavulanic acid 0.0 20.0 16.6
Piperacillin tazobactam 98.7 0.5 25.0
Ampicillin Sulbactam 57.8 0.0 0.0
Cephalosporins and inhibitors (%)
Cefoperazone sulbactam 11.5 15.0 16.6
Polymyxins (%)
Colistin 1.2 0.5 0.0
Polymyxin B 0.0 0.0 0.0
Type of resistance
Sensitive (%) 1.4 65.0 58.3
MDR (%) 11.5 30.0 16.6
XDR (%) 86.9 0.0 25.0
PDR (%) 0.0 0.0 0.0
The number of HAIs caused by the A. baumannii strains significantly fluctuated in the years under
studyexamined herein, most frequently in 2008–2009, and a rapid trend of A. baumannii resistance to
carbapenems was observed (Table 7).
Table 7. Compilation of the number of Acinetobacter baumannii isolates resistant to carbapenems in the
years 2007–2016.
Year Number of Acinetobacter baumannii Isolates
Imipenem Meropenem
n (%) n (%)
2007 11 1 (9.1) 0 (0.0)
2008 26 2 (7.7) 1 (3.8)
2009 26 3 (11.5) 2 (7.7)
2010 7 1 (14.4) 4 (57.1)
2011 3 1 (33.3) 1 (33.3)
2012 13 6 (46.2) 9 (69.2)
2013 4 1 (25.0) 3 (75.0)
2014 11 7 (63.6) 7 (63.6)
2015 13 10 (76.9) 10 (76.9)
2016 6 4 (66.7) 3 (50.0)
totality 120 36 (30.4) 40 (33.3)
n (%): number and percentage of strains resistant to imipenem and meropenem.
4. Discussion
The results of our single-centre study are among the very few available in Poland. The study
has a limited character because observational single-centre studies cannot be treated as a benchmark
for all the population of Polish patients treated in ICUs. Therefore, the results of the study should be
treated as an information basis on which preventive strategy of HAIs should be built accompanied by
active methods of supervision aimed at improving the safety of patients treated in ICUs. It is not easy
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to assess the condition of a critically ill patient treated in ICU and it is not always possible because
of the dynamics of pathological changes and the intensity of treatment. Thus, the next limitation for
the studies is lack of proper classification of patients’ condition based on APACHEII and SOFA scale.
Lack of such an evaluation in the group of 1849 patients treated in ICUs within 10 years resulted in not
including the results of several hundred patients into the total analysis. That is why the study is focused
mainly on evaluation of various types of HAIs and their determinants. In our ICU, the incidence of
HAIs was 28%. The results obtained were similar to the results obtained in the meta-analysis performed
by Allegranzi et al. [4], in which the incidence was 30%. In one of the single-centre studies conducted
in Poland by Wieder-Huszla [2] in 2010, the incidence of HAIs was 24%. Additionally, Kübler et al. [3]
conducted another single-centre study in Poland in 2012 and reported the incidence of HAIs as 24%.
In the point prevalence survey (PPS) based on morbidity and performed in Poland in 2011–2013,
morbidity in the ICU was 35%. In the literature, lower HAI incidence rates have also been reported,
ranging from 9% to 16% [5,15]. In our ICU, the mortality of patients with healthcare-associated
infections was 12%. The result is similar to the mortality rate reported in the 2007 ECDC report, with an
average mortality rate ranging to 15% [1]. Agodi et al. [16] detected 18% mortality in the ICU examined.
The average age of patients treated in the ICU was 58 years, with a predominance of men, and the ratio
of men to women was 1.55. In other European countries, the average age of patients was 61, and the
sex male-to-female ratio was 1.56 [1]. In Rosenthal et al. [17], the average age of patients was 60 years.
This analysis indicated that the patients in the analysed ward were younger, which may imply a worse
health status in the Polish population and an earlier incidence of the diseases than in the compared
countries. In our study, the duration of a patient’s stay in the ICU was 19 days for patients without
HAIs and as many as 55 days for patients with HAIs. In European countries, the length of ICU stays
was between 8 and 13 days (the average amounting to 10 days) [1]. The extended stay of patients in
the examined ward may be related to a different healthcare organization in Poland as well as to the
infrastructure of the hospital wards, whose managements are afraid of accepting and continuing the
treatment of a patient in a difficult state of health [18]. For patients with HAI, their longer stays may
be related to the location of the infection as well as to the species of infecting micro-organism and its
susceptibility to antibiotics [19,20].
Pneumonia was most frequently diagnosed, the incidence being 10%. In the ECDC report,
which included data from 2007 [1], the average incidence was lower at 7%, but the differences between
European countries were large and ranged from 3% to 36%. In a subsequent ECDC report in 2014,
the average incidence was 6% [21]. In Rosnthal et al. [22] report from 50 countries the VAP incidence
ranged between 0.9 and 13.1 per 1000 ventilator-days. Ventilator associated pneumonia density in the
American CDC NHSN program from 2012 was on average 0.9 per 1000 ventilator-days [23]. In the
present study, the IAP density was 15 in 1000 days with intubation. In European countries, in a study
published in 2012, the mean density of IAP was 8 in 1000 with intubation [1]. In Rosenthal et al. [17]
the IAP density in different ICUs ranged from 10 to 53 per 1000 days with a respirator. In another
study of 43 countries, 17 patients were treated with a respirator [24]. In ECDC reports published in
the last few years the mean device-adjusted rate was 10 IAP episodes per 1000 intubation days and
varied between 3 (UK-Scotland) and 16 (Italy) in 2014; 2 (Luxembourg) and 18 (Italy) in 2015 [25,26].
In a single-centre study conducted in Poland in the ICU in 2012/2013/2014, the prevalence of a
IAP was 11/9/10 for 1000 days with intubation, respectively [27]. The average time between the
admission to the onset of PN in our study was 19 days (median 15 days). In an ECDC report, the mean
incubation time from ICU admission to the onset of pneumonia was 16 days (median 10 days) [1].
In our study, the duration of hospitalization for PN patients was 52 days on average (median 38 days),
which means a significant, almost three-fold increase in hospitalizations in comparison with that of
non-infected patients. Another study conducted in Poland confirmed the long 36-day hospitalization
of PN patients [28]. In the ECDC study, the duration of hospitalization of patients with PN was
approximately 3.5 times higher than that of patients without PN [1]. In the further part of our own study,
PN subtypes were identified (based on diagnostics), with PN4 dominating (145 cases (79%)). Similar
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evidence can be found in the ECDC report, in which there were approximately 50% of PN4. However,
there were significant differences between the countries surveyed [1]. A. baumannii (41%), P. aeruginosa
(12%), S. aureus and E. coli (9%) and K. pneumoniae (8%) were predominant in our study. For comparison,
in the ECDC study pneumonia was most commonly caused by the following: P. aeruginosa (19%),
S. aureus (16%), and E. coli (9%) [1]. In another ECDC study conducted in 2011–2012 for infections
in European countries, PN was predominant in Pseudomonas aeruginosa (17%), Staphylococcus aureus
(13%), and Klebsiella spp. (11%) [29]. The ECDC study found the same microorganisms in a similar
proportion, the only difference being a more frequent occurrence of Acinetobacter baumannii in our ICU.
Acinetobacter baumannii also predominated in PNs detected in ICU in other Polish studies [2,27]. In a
study by Chmielarczyk et al. [30], Acinetobacter baumannii induced 79% of PN. It can therefore be
concluded that similar PN aetiological factors are present in regions of Poland and other European
countries. The mortality rate in our study was 45%.
The second-most common type of HAI was bloodstream infections (BSIs), with a 9% incidence.
In the 2007 ECDC report, the incidence in European countries ranged from 2% to 5% (on average 4%) [1].
In a subsequent ECDC report published in 2015, the incidence was 3% [21]. In our study, the density
of catheter-associated bloodstream infections (CLA-BSI) was 8 per 1000 central-line days. As the 2012
European ECDC report reported, the density of bloodstream infections with CLA-BSI varied between
2 and 5 in 1000 central-line days in Europe (the average being 3 in 1000 CVC days) [1]. Comparing our
findings with those from European programmes, it could be observed that bloodstream infections are
twice as common in our study in the incidence rates and densities. In another study conducted in 55
ICUs in developing countries, the density of bloodstream infections with CLA-BSI ranged from 8 to 19
per 1000 central-line days (average of 13 per 1000 central-line days) [17]. Rosnthal et al. [22] in the report
INICC 2010–2015 from 50 countries CLA-BSI ranges between 0.8 and 4.1 per 1000 central-line days.
CLA-BSI density obtained in the American CDC NHSN program in 2012 was on average 1.8 per 1000
central-line days [23]. In ECDC report from 2014 the mean device-adjusted rate was: 2.4 CLA-BSI
episodes per 1000 central-line days [26]. In ECDC from 2015 the mean device-adjusted rate was 3.6
CLA-BSI episodes per 1000 central-line days and varied between 1 (Luxembourg) and 8 (Slovakia) [25].
The obtained results classified the occurrence of catheter-associated bloodstream infections in Poland
at the lower border of developing countries with respect to CLA-BSI prevalence. In another study
of 43 countries, the density was 5 per 1000 CVC days [24]. The average time between admission
to BSI was 24 days (median 16 days). In the ECDC report [1], the onset of BSIs occurred on day
20 (median 14 days). In our BSI study, the following physiological flora were dominant in BSIs:
Coagulase-negative staphylococci (44%), A. baumannii (17%), and S. aureus (6%). The results obtained
were comparable to those reported in the 2012 ECDC study for CLA-BSIs [1], where coagulase-negative
staphylococci was present in 41%, S. aureus was present in 13%, and Enterococcus spp. was present
in 12%. In the 2017 ECDC report [26], coagulase-negative staphylococci were similarly dominant. In a
study by Chmielarczyk et al. [30] conducted in Poland in 2016, Acinetobacter baumannii was detected
in 17% cases in BSI in ICU. The mortality rate for BSIs was 45%. In a study carried out in Poland by
Wójkowska-Mach et al. [31], the mortality rate related to primary blood infection in ICU was higher
and amounted to 19%. In the 2007 ECDC report, mortality in BSIs averaged 33% (21% to 40%) [1].
The third-most common form of hospital infection was urinary tract infections. In our study,
the incidence rate was 3%, and the density of UTI with catheter-associated urinary tract infection
(CA-UTI) amounted to 3 per 1000 catheter days. In a single-centre study conducted in Poland by
Duszyńska et al. [32], the incidence rate was 7%. In the 2007 ECDC report, the incidence in European
countries was 7%, and the density was 1 to 21 (with an average of 5 per 1000 catheter days) [1].
In Rosnthal et al. [22] INICC 2010–2015 raport from 50 countries CA-UTI ranges from 1.7 to 5.1 per
1000 catheter days. CA-UTI Density in American CDC NHSN program from 2012 was on average
1.7 per 1000 catheter days [23]. In a study conducted in 2006 in 55 intensive care units in developing
countries, the incidence of CA-UTI ranged from 2 to 13 per 1000 catheter days [17]. In a study of
43 countries conducted in 2014, the density was 5 per 1000 catheter days [24]. The lower CA-UTI
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scores, which we obtained, may be due to the weakness of the HAI surveillance structures and little
experience in this field [18]. In ECDC from 2014 and 2015 the mean device-adjusted rate was 4
CA-UTI episodes per 1000 catheter days [25,26]. In the ECDC report [1], the onset of UTI was on
the twenty-first day of residence (median: 15 days). In the ICU under our examination, the onset of
UTI was on average 30 days (median: 24 days), and the average hospitalization time was 62 days
(median 54 days), which implies a significant increase in hospitalization for non-infected patients.
In our study, UTIs was dominated by the following microbiota: Candida albicans (20%), E. coli (19%),
and P. aeruginosa (11%). The microbiota detected in our study was similar to the one from 2007 ECDC
report: Escherichia coli (25%), C. albicans (17%), and Enterococcus spp. (18%). The UTI mortality rate
was 41%. In the European study, a large variation—between 7% and 37%—in UTI mortality rates was
observed [1].
In the ICU in our study, other types of healthcare-associated infections were present: GI (2%),
SSI (2%), SST (1%), and OTH (1%). In a multicentre prevalence-based study, healthcare-associated
infections were detected in the ICU in slightly different percentages: GI (morbidity 4%), SSI (9%), SST
(3%) and OTH (4%) [10].
In the present study, the prevalence’s of multidrug resistance (MDR) strains was maintained
at a similar level in particular years: Staphylococcus aureus MRSA (21%), MRSE coagulase-negative
staphylococci (36%), ESBL Escherichia coli (7%), Klebsiella spp. (23%), and Enterococcus spp. (31%). In the
2007 ECDC report, the findings were as follows: Staphylococcus aureus MRSA (35%), coagulase-negative
staphylococci (83%), E. coli ESBL (12%), Klebsiella spp. (23%) [1,21], Escherichia coli ESBL (12%), Klebsiella
spp. (26%), Staphylococcus aureus MRSA (25%), and Enterococcus spp. (25–50%) [21]. However, in
other studies, a clear trend was observed for antimicrobial resistance, especially among Gram-negative
bacilli [19,20,29]. The 2017 ECDC report [26], provided the following results: 25% Staphylococcus aureus
MRSA, 17% ESBL E. coli, 44% Klebsiella spp., and 44% Enterobacter spp.
Clinical specimens from HAI patients were isolated from multidrug resistance (MDR) strains,
which implies insufficient sensitivity to at least one antibiotic from three or more antimicrobial
drug classes active against the species. In our study, 30% of Staphylococcus aureus strains showed
methicillin resistant (MRSA) strains, but no vancomycin resistant strains (VRSA) were detected.
The stabilization of MRSA infections and the small percentage of Gram (+) microorganisms resistant
to vancomycin-resistant bacteria has been observed in the literature [19]. A literature analysis shows
that the growth in resistance to antibiotics of Gram (−), especially K. pneumoniae [19,20,22,26,29] is
on the increase. In the present study, the percentage of K. pneumoniae resistant to third-generation
cephalosporins ranged from 17% to 67%. In a study conducted under the PPS (ECDC) programme
in Europe in 2012, K. pneumoniae, isolated from invasive infections, showed, on average, a 26%
resistance to third-generation cephalosporins (from 2% to 79%); in Poland, K. pneumoniae showed a
73% resistance [29].
While analysing the antimicrobial resistance of antibiotics, Acinetobacter baumannii was found to
be 87% extensive-drug resistant (XDR), which means there was insensitivity to one or more antibiotics
in all but two or fewer classes of antibiotics. Based on a review of the literature and the observed trends
of resistance among Acinetobacter baumannii, the results obtained in our own study were comparable to
the results of reports from European countries, where the microorganism displayed a wide spectrum of
resistance [29]. In a study by Chmielarczyk et al. [30], extensive drug resistant strains (XDR) accounted
for 80.8% of the tested isolates and were detected in HAI patients in the ICU. Therefore, monitoring
drug resistance of A. baumannii strains in ICUs is vital with respect to planning specific infection control
measures to prevent the spread of MDR and XDR to other patients.
According to Różańska et al. [33], in Poland, infection control programmes are a challenge for
the future, and their implementation requires increasing the awareness of both medical staff and
hospital management. The presented results constitute some of the research based on the method of
active, continuous surveillance of infections in the ICU in Poland. The results obtained confirm the
reliability of surveillance conducted in the ICU under examination. The results can provide a basis for
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comparing the epidemiological situation in other ICUs, which may accordingly contribute to effective
HAI prevention.
5. Conclusions
(1) In the ICU study, pneumonia and bloodstream infections were the most common.
(2) Acinetobacter baumannii strains were most commonly isolated from clinical specimens collected
from HAI patients.
(3) The number of Acinetobacter baumannii infections did not have a tendency during the
period considered.
(4) The strains of Acinetobacter baumannii mostly showed resistance to many antibiotic groups.
(5) There was a trend of an increasing resistance of Acinetobacter baumannii to carbapenems.
(6) Action is needed to limit the spread of these strains.
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Abbreviations
HAIs Healthcare-Associated Infections
DA-HAI Device-Associated Healthcare-Associated Infection
ICU Intensive Care Unit
ECDC European Centre for Disease Prevention and Control
PN Pneumonia
IAP Intubation Associated Pneumonia
VAP Ventilator Associated Pneumonia
PN2 Non-protected sample with quantitative culture
PN3 Alternative microbiological criteria
PN4 Sputum bacteriology or non-quantitative
PN5 No microbiological documentation
BSI Bloodstream Infection
CVC Central Venous Catheter
CLA-BSI Central Line-Associated Bloodstream Infection
BSI-C Vascular Catheter-Related
CRI1-CVC Primary BSI local Catheter Related Infection
CRI2-CVC Primary BSI general Catheter Related Infection
CRI3-CVC Primary BSI microbiologically confirmed Catheter Related
BSI UO Primary BSI of Unknown Origin
BSI-S Secondary BSI to another infection: DIG, PUL, SSI
UTI Urinary Tract Infections
CA-UTI Catheter-Associated UTI
UTI-A Microbiologically confirmed symptomatic
UTI-B Not microbiologically confirmed symptomatic urinary tract infection
GI Gastrointestinal
GI-CDI Clostridium difficile infection
GI-GE Gastroenteritis
SSI Surgical Site Infection
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SSI-D Deep incisional
SSI-O Organ/space
SSI-S Superficial incisional
SST Skin and Soft Tissue Infection
SST-DECU Decubitus ulcer
SST-SKIN Skin infection
SST-ST Soft tissue
CNS Central Nervous System Infections
EENT Eye, Ear, Nose, Throat or Mouth Infection
LRI Lower Respiratory Tract
SYS Systemic Infections
OTH Other Infections
BAL Broncheoalveolar Lavage
CFU Colony Forming Unit
XDR Extensive Drug Resistant
PDR Pan Drug Resistant
MDR Multi Drag Resistant
EUCAST European Committee on Antimicrobial Susceptibility Testing
p Significance level
Me Median
SD Standard Deviation
95% CI Confidence Interval
OR Odds ratio
DUR Device Use Ratio
INICC International Nosocomial Infection Control Consortium
NHSN National Halthcare Safety Network in USA
APACHEII Acute Physiology And Chronic Health Evaluation II score
SOFA Sepsis-Related Organ Failure Assessment score
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